Shots:
- Kaigene has granted Celltrion exclusive global rights to develop & commercialize KG006 (excl. Greater China & Japan) & KG002
- As per the deal, Kaigene will receive $8M upfront, & ~$736M in milestone payments, incl. $11M in near-term milestones through the initiation of P-I trials, along with net sales-based tiered royalties
- KG006 is an FcRn inhibitor with a novel antibody design for extended durability, while KG002 is a dual-acting antibody that degrades autoantibodies & suppresses disease-specific B cells
Ref: PRNewswire| Image: Kaigene & Celltrion | Press Release
Related News:- Manifold Bio Partners with Roche to Develop BBB shuttles for Neurological and Neurodegenerative Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
